"Transparency” has become the new industry buzzword. Clinical Trial (CT) Disclosure regulatory requirements continue to increase with mandatory registries and an expanding scope of required disclosure data, including the transparency initiatives announced by the EMA1, EFPIA2 and PhRMA3.

As a result, sponsors are under increasing pressure to make CT data that has not traditionally been disclosed on registries available to the public.

Quintiles is pleased to introduce a clinical trial disclosure group that is dedicated to providing you a single-source solution as you pull together the different elements required by new public disclosure and transparency guidelines and regulations.